Esophageal squamous cell carcinoma (ESCC) is one of the most frequent causes of cancer death worldwide and effective diagnosis is needed. We assessed the diagnostic potential of an autoantibody panel that may benefi t early diagnosis.
INTRODUCTION
Esophageal cancer is the eighth most common malignant disease and the sixth leading cause of cancer-related death worldwide ( 1 ) . China is one of the regions with the highest incidence rates, and 90 % of cases are esophageal squamous cell carcinomas (ESCCs) ( 2 ) . ESCC mortality and incidence rates are similar, and the 5-year overall survival rate is below 15 % ( 1,3 ). Th is outcome is partly because of the lack of a screening strategy for timely diagnosis. Patients with localized disease have better survival rates than those with metastatic disease ( 4 ) . However, most cases of ESCC oft en present at an advanced stage at the time of diagnosis ( 5 ) . Failure of local control remains a signifi cant clinical problem. Th erefore, a noninvasive method for the early detection of ESCC is urgently needed and would represent an important clinical advancement in the management of patients. Current blood tests mainly identify circulating tumor antigens that are elevated Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma most commonly in patients with metastatic disease and appear to refl ect tumor bulk. Serum markers for ESCC in clinical use, such as carcinoembryonic antigen, squamous cell carcinoma antigen, and CYFRA21-1, are not suffi ciently sensitive for early diagnostic purposes ( 6 -8 ) .
Evidence of the humoral immune response, in the form of autoantibodies, to tumor-associated antigens (TAAs) has created opportunities for exploiting the immune system as a source of cancer biomarkers. Autoantibodies have been found to precede manifestations of symptomatic cancer by several months to years ( 9 -12 ) , making their identifi cation of particular relevance for early detection. Nonetheless, measurement of a single autoantibody may lack suffi cient sensitivity required for cancer screening and diagnosis ( 13 ) . In order to overcome this problem, subsequent studies have provided better sensitivity in the diagnosis of cancer by screening for multiple autoantibodies toward a panel of TAAs ( 10,14 -21 ) . However, most of these reports had limitations, such as small study size and single-cohort study design. Th is underscores the diffi culty in gaining access to human samples.
In this study, we assessed the diagnostic accuracy of autoantibodies to a panel of TAAs for ESCC, and validated the results in an independent population. A panel of six antigens was selected for investigation and comprised a number of well-recognized TAAs (p53, NY-ESO-1, matrix metalloproteinase-7 (MMP-7), heat shock protein 70 (Hsp70), peroxiredoxin VI (Prx VI), and BMI1 polycomb ring fi nger oncogene (Bmi-1)) that have been shown to induce the production of autoantibodies in ESCC ( 22 -27 ) . In brief, p53 is a tumor-suppressor gene that was described as the fi rst antigen to elicit autoantibodies in cancer ( 28 ) . Importantly, autoantibodies to this protein have also been detected in some cases before cancer diagnosis ( 11, 12 ) . Furthermore, p53 autoantibodies have been detected in diff erent cancer types, including ESCC ( 29 ) . Cancer / testis antigen 1B (NY-ESO-1), whose expression is present in some solid tumors, has previously been shown to induce autoantibodies in esophageal cancer ( 27, 30 ) . MMP-7, the smallest of the matrix-degrading metalloproteinases that play an important part in degradation of extracellular matrix, is highly expressed in early stages of cancer and has been described as capable of inducing an autoantibody response in ESCC ( 26, 31 ) . Autoantibodies to Prx VI, a member of the thiol-specifi c antioxidant protein family, have been considered to be a specifi c serologic marker for ESCC ( 22 ) . Th e Bmi-1, a transcriptional repressor belonging to the polycomb group family, has been described as eliciting an autoantibody response in the sera of patients with ESCC as well ( 25 ) . Th e fi nal antigen in the panel, Hsp70, has been previously identifi ed in sera from patients with ESCC by using a proteomics-based approach and has been shown to be a highly immunogenic antigen in ESCC ( 23 ) .
METHODS

Study population
We recruited patients with ESCC to a test cohort, from the Department of Th oracic Surgery, the Cancer Hospital, Shantou University, Guangdong, China, from July 2011 to July 2012. A validation cohort comprising patients with ESCC was recruited from the Department of Oncological Surgery, Shantou Central Hospital, Sun Yat-sen University, Guangdong, China, from October 2007 to July 2012. Th e normal controls in the test cohort were from the staff of the Cancer Hospital, and the normal controls in the validation cohort were eligible blood donors with no previous malignant disease ( Table 1 ) .
ESCC was defi ned on the basis of gastroscopy and spiral computed tomography, and was confi rmed by histopathology. Tumor stage, determined from resected tumors, was defi ned according to the seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual ( 32 ) . Tumor stage of patients without tumor resection was defi ned according to the proposal of the Chinese panel of experts for nonsurgical treatment of esophageal cancer on clinical stages ( 33 ) . For the purpose of this study, we classifi ed tumors with AJCC stage 0 + I + IIA as early-stage ESCC.
Patients from the two centers were all newly diagnosed. Sera of these patients were obtained at the time of diagnosis before any treatment. Sera of patients in the validation cohort were routinely obtained and kept in a bank for research. Peripheral blood samples were centrifuged at 1250 g for 5 min and stored at − 80 ° C until use. Patients with esophageal adenocarcinoma were excluded from the study. Two independent researchers (Yu-Hui Peng and Chun-Peng Zheng) were responsible for data collection.
Before the use of these clinical materials for investigation, approval for the study from the institutional ethics review committee at each study center and informed consent of patients were obtained.
Expression and purifi cation of recombinant TAAs
See Supplementary Materials and Methods online for detail.
Autoantibody detection
Enzyme-linked immunosorbent assay for serum autoantibodies was performed by two researchers (Yi-Wei Xu and Bo Chen) who had no access to patient clinical information. Briefl y, purifi ed recombinant antigens, p53, NY-ESO-1, MMP-7, Hsp70, Prx VI, and Bmi-1, were diluted in 50 m M bicarbonate buff er (pH 9.6) to a fi nal protein concentration of 0.1, 0.1, 0.6, 0.8, 1.5, and 0.6 μ g / ml, respectively. Serum samples and quality control samples (a pooled plasma sample collected randomly from 100 patients with ESCC) were diluted 1:110 in blocking buff er, and then incubated at 37 ° C for 1 h, as well as were appropriate control rabbit polyclonal antibodies (Immunosoft , Zhoushan, China) specifi c for capture proteins. Aft er washing, horseradish peroxidase-conjugated goat anti-human IgG or anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were used as secondary antibodies at the dilution recommended by the manufacturer. Aft er a 60-min incubation, the plates were washed, and ready prepared 3,3 ′ ,5,5 ′ -tetramethylbenzidine (InTec PRODUCTS, Xiamen, China) and hydrogen peroxide (InTec PRODUCTS) were added. Color formation was allowed to proceed for 15 min and then stopped with 0.5 M H 2 SO 4 . Th e absorbance of each well was read at 450 nm within 5 min by a plate microplate reader (Th ermo Fisher Scientifi c, Boston, MA).
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All cancer and normal samples were interspersed on the plates and run in duplicate. Quality control samples were run to ensure quality control monitoring of the assay runs by using Levey -Jennings plots. With the purpose of minimizing an intraassay deviation, the ratio of the diff erence between duplicated sample optical density values to their sum was used to assess precision of the assay. If the ratio was > 10 % , the test of this sample was treated as being invalid and the sample was repeated.
Assay cutoff values
Th e cutoff value designating positive reactivity was defi ned as an optical density value greater than the mean plus 3 s.d. of the normal controls from the test cohort ( 14, 19 ) . Specifi city of the assay was calculated as the percentage of normal controls who gave a negative result.
Statistical analysis
All analyses were done using SPSS (version 17.0, Chicago, IL), Microsoft Excel (Redmond, WA), or GraphPad Prism soft ware (La Jolla, CA) . Th e number and proportion of positive samples were presented with 95 % exact confi dence interval (95 % CI) for binomial proportions ( 34 ) . Th e false positive rate, false negative rate, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio, all with 95 % CIs, were presented to improve clinical interpretation. Th e χ 2 tests or Fisher ' s exact tests were carried out to fl ag where the proportion of positive results was signifi cantly diff erent between cancer groups and the normal controls, and to identify correlations of individual and combined antibody assay positivity with clinical parameters. In all tests, we considered P values of < 0.05 (two sided) to be signifi cant.
RESULTS
Autoantibodies in ESCC
In total, 884 participants were recruited, 513 in the test cohort and 371 in the validation cohort ( Figure 1 ). Patient and normal control demographics and tumor clinicopathological characteristics are shown in Table 1 .
Th e presence of autoantibodies to all TAAs in both cohorts is shown for one concentration of antigen in the scatter plots in Figure 2 . When compared with the sera of normal controls, elevated levels of autoantibodies for all six TAAs were clearly present and similar in ESCC individuals in both cohorts.
Levels of autoantibodies to individual antigens in the ESCC groups and normal controls are shown in Table 2 . In the test cohort, patients with ESCC were signifi cantly diff erent from the normal controls in individual autoantibodies. Individual autoantibodies were elevated between 9 % (95 % CI: 6 -12 % ) and 30 % (95 % CI: 25 -35 % ) in ESCC sera. Use of these 6 autoantibody assays provided an enhanced panel sensitivity of 57 % (95 % CI: 52 -62 % ) and panel specifi city of 95 % (95 % CI: 89 -98 % ). Th e importance of autoantibody responses to individual antigens in the panel assay varied. Th ere was a higher percentage of positive reactions to p53 antigen and NY-ESO-1 antigen, whereas positive reactions to MMP-7, Hsp70, Prx VI, and Bmi-1 were lower. Some TAA signals overlapped in cancer cases. In 23 % of the seropositive individuals in panel 1 of 6, autoantibodies were raised to a second antigen in ESCC samples in the test cohort ( Supplementary Figure S1 online ). Th is was refl ected in the observation that a restricted panel consisting of the four antigens p53, NY-ESO-1, Hsp70, and Prx VI exhibited only a slightly reduced sensitivity of 55 % (95 % CI: 50 -60 % ), but with an increased specifi city of 98 % (95 % CI: 93 -99 % ) in the test cohort ( Tables 2 and 3 ). 
Autoantibody panel for early detection
In the test cohort, 53 patients with ESCC had early-stage disease (AJCC stage 0 + I + IIA in patients with tumor resection). Positive frequencies of the autoantibody panel were signifi cantly higher in these patients than those in normal controls ( P < 0.0001, Table 4 ). Th e ability of the autoantibody panel to distinguish early-stage patients from normal controls was confi rmed in the validation cohort ( Table 4 ). In the test cohort, panel sensitivity for the detection of early-stage ESCC was 45 % (95 % CI: 32 -59 % ), with specifi city at 95 % (95 % CI: 89 -98 % ), and similar results were obtained with the validation cohort ( Table 5 ). Restriction of the panel to the presence of p53, NY-ESO-1, Hsp70, and Prx VI autoantibodies exhibited almost the same diagnostic performance for early-stage ESCC ( Table 5 ) .
In both the test cohort and validation cohort, within the earlystage groups, 4 patients with tumor resection were confi rmed to have stage 0 disease, and the autoantibody panel gave a positive P value is relative to normal controls ( χ 2 tests). * P < 0.0001; * * P < 0.001; * * * P < 0.01. 
Effect of clinicopathological features on autoantibody assay sensitivity and specifi city
Th e eff ect of patient demographics or tumor characteristics on variation in the specifi city / sensitivity is demonstrated in Figure 3 and Supplementary Table S1 online . In the test cohort, there were no signifi cant diff erences in sensitivity of the autoantibody panel when the ESCC samples were subdivided by patient age, gender, smoking status, size of tumor, site of tumor, depth of tumor invasion, histological grade, lymph node status, TNM stage or early-stage and late-stage groups ( P > 0.05, Figure 3 and Supplementary Table S1 ). Sensitivity of the autoantibody panel according to patient demographics or tumor characteristics was further confi rmed with no signifi cant diff erence in the validation cohort ( P > 0.05, Figure 3 and Supplementary on incidence screening in lung cancer and can be detected in the asymptomatic stage of breast cancer up to 5 years before the onset of disease ( 10, 37 ) . Our study further supports previous publications indicating that the induction of autoantibodies occurs early in the process of carcinogenesis. Th e positive frequencies of our autoantibody panel in the early-stage ESCC group were 45 % (95 % CI: 32 -59 % ) in the test cohort and 46 % (95 % CI: 35 -58 % ) in the validation cohort. Th us, our autoantibody panel improves the diagnostic performance in early-stage ESCC samples, compared with other biomarkers (e.g., CYFRA21-1 and squamous cell carcinoma antigen) currently used in clinical practice ( 6 -8 ) . For example, positive frequencies of CYFRA21-1 are reported to be only 4.7 % and 25 % in stage I and stage II cancers, respectively ( 7 ). For squamous cell carcinoma antigen, positive frequencies in patients with stage 0 + I and stage II have been reported to be 10.8 % and 24.0 % , respectively ( 8 ) . However, the measurement of the autoantibody panel does not seem sensitive enough, with false negative rates of 43 % (95 % CI: 38 -48 % ) and 55 % (95 % CI: 41 -68 % ) in patients with ESCC and early-stage ESCC in the test cohort, respectively. Similar results were observed in the validation cohort ( Table 3 ) . Such a high false negative frequency will prevent the timely diagnosis of ESCC for some patients, particularly the symptomless, early-stage patients. Th us, a further search for autoantibodies with high sensitivity will be the focus of future studies. Th is autoantibody panel assay has excellent specifi city for ESCC, especially for the early stage. Th e robust specifi city of the test, as a prerequisite to be useful to aid in early detection, indicates that our autoantibody panel should make a signifi cant contribution to the diagnosis and screening of ESCC patients. However, in screening a large population where the prevalence of ESCC is low, as a result of low sensitivity and large population, even with a very low false positive rate, many false positive results will be obtained . Th erefore, if measurement of the autoantibody panel is used as a screen for ESCC, no correlation with any of the variables ( Supplementary  Table S4 ).
DISCUSSION
Because of the lack of specifi c symptoms in patients with earlystage ESCC and the lack of reliable noninvasive screening tests, early detection is hampered. Currently, the diagnosis of ESCC is based on endoscopic examination followed by histological analysis of biopsy, an invasive technique not suitable for the screening of asymptomatic populations. In this study, we have demonstrated that the detection of autoantibodies to selected tumor-associated antigens in the peripheral blood has potential diagnostic value for ESCC. More than half of the ESCC patients examined had autoantibodies to at least 1 of the 6 TAAs, with a specifi city of at least 95 % . Th e sensitivity and specifi city of the autoantibody panel in this study are in broad agreement with published data for individual autoantibody assays in other cancers such as lung, breast, colorectal, gastric, and prostate cancers, and further confi rm that application of several autoantibodies would detect cancer with higher effi ciency than a single biomarker ( 14,16 -20,22,23,26,35 ) . Consistent with prior reports ( 16, 17, 19 ) , no signifi cant diff erence was seen in autoantibody detection of cancer when patients were subdivided by tumor characteristics. Th is is in contrast to detection of the tumor-associated antigens that are markers of tumor burden and not useful for the early detection of ESCC ( 6 -8 ) .
Identifi cation of novel serum biomarkers for the diagnosis of cancer, especially for detection and screening in early-stage cancer, is an important means to improve clinical outcome ( 36 ) . Previous publications about other tumors have given prominence to the potential value of a panel of autoantibodies for the early detection of cancer ( 10,14 -20 ) . Using a panel of antigens, autoantibodies can be detectable as early as 5 years before radiographic detection especially for early-stage patients in a general population, further diagnosis should involve additional imaging tests, such as gastroscopy. As a screen, our autoantibody test may be more appropriate for regions with high incidence rates of ESCC. Whether measurement of autoantibodies may have a role in populations with diff erent ESCC prevalences needs further validation. In the future, we will use our autoantibody test to screen for ESCC in regions with high incidence rates in a prospective study. Patients with a positive autoantibody test would undergo gastroscopy or another imaging technology to detect early tumor lesions. If esophageal (or other) cancer is verifi ed by imaging, then defi nitive treatment could be carried out earlier.
Each antigen in the panel has been shown to be capable of inducing autoantibodies in patients with ESCC. However, measurement of autoantibodies to MMP-7, Prx VI, Hsp70, and Bmi-1 did not signifi cantly improve the assay. Th e low levels of autoantibodies to MMP-7, Prx VI, Hsp70, and Bmi-1 emphasize that the combination of an optimized panel to measure these autoantibodies has to be selective for high sensitivity and specifi city. In contrast, measurement of the autoantibody responses to p53 and NY-ESO-1 antigens is integral to the panel assays. Previous studies, investigating the presence of autoantibodies to NY-ESO-1 antigen in lung cancer and breast cancer, demonstrate similar levels of sensitivity and specifi city as reported here ( 16, 17 ) . Th e clinical use of autoantibodies for screening and early diagnosis appears to depend on fi nding an optimized panel of autoantibodies. Th e restricted panel consisting of the four antigens p53, NY-ESO-1, Hsp70, and Prx VI exhibited almost the same diagnostic performance as when screening for all six autoantibodies. Taking into account the cost -benefi t, autoantibody assays against the restricted panel is acceptable for aiding the early detection of ESCC. Th e advantage of this method is that the full range of heterogeneous esophageal cancers can be detected by increasing the number of TAAs or altering the antigens used in the panel. Many proteomics-based technologies, such as serological analysis of tumor antigens by recombinant complementary DNA expression cloning ( 38 ) , phage display ( 39 ) , and serological proteome analysis ( 40 ) , have been used for the detection of antigen-specifi c antibodies. Th erefore, an increasing number of other cancer-specifi c immunoreactive antigens is continually being described. Recent publications have reported additional antigens, such as the ATP-binding cassette, sub-family C, member 3 (ABCC3), and cell division cycle 25B (CDC25B), that induce the production of autoantibodies in ESCC ( 41, 42 ) . Whether these antigens can enhance the diagnostic effi ciency of the autoantibody panel remains to be investigated.
Th e sample size and the proportion of patients with diff erent tumor characteristics in our test cohort were diff erent from those in the validation cohort ( Figure 1 and Table 1 ). Th erefore, to a certain extent, the groups diff ered in diagnostic performance ( Tables 2 -5 and Figures 2 and 3 ). For example, because the number of patients with later-stage tumors, in which the autoantibody responses to the panel seemed more prevalent, was larger in the test cohort than that in the validation cohort, the sensitivity of the autoantibody panel diff ered between two cohorts ( Tables 2 and 3 ). Despite these diff erences, the diagnostic performance of the autoantibody panel was generally similar in the test and validation cohorts. We believe that the autoantibody panel has diagnostic potential for ESCC because its value in the test cohort was confi rmed in an independent validation cohort.
In summary, this is a large study to report the clinically diagnostic relevance of an autoantibody assay using a panel of specifi c autoantibodies as potential serum markers for ESCC. Our results reveal that an autoantibody blood test, which is noninvasive, cost eff ective, and has no side eff ects, may act as an aid to diagnose ESCC, especially in the early-stage ESCC.
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